Soleno Therapeutics to Participate in the BIO CEO & Investor Conference

Rhea-AI Summary

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced its CEO Anish Bhatnagar will present a corporate overview at the BIO CEO & Investor Conference on February 15, 2022, at 2:15 PM Eastern Time. The company focuses on developing novel therapeutics for rare diseases. Its lead candidate, DCCR extended-release tablets, is in Phase 3 clinical development for treating Prader-Willi Syndrome (PWS). For more information, visit www.soleno.life.

News Market Reaction – SLNO

+2.20%

+2.20% Session move

In the trading session that priced this news, SLNO gained 2.20%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:15 PM Eastern Time.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

What is the date and time of Soleno Therapeutics' presentation at the BIO CEO & Investor Conference?

Soleno Therapeutics' presentation is on February 15, 2022, at 2:15 PM Eastern Time.

Who will represent Soleno Therapeutics at the BIO CEO & Investor Conference?

Anish Bhatnagar, M.D., the Chief Executive Officer, will represent Soleno Therapeutics.

What is the focus of Soleno Therapeutics?

Soleno Therapeutics focuses on developing novel therapeutics for the treatment of rare diseases.

What is DCCR and for which condition is it being developed?

DCCR is an extended-release tablet currently in Phase 3 clinical development for treating Prader-Willi Syndrome (PWS).

Where can I find more information about Soleno Therapeutics?

More information can be found on Soleno Therapeutics' website at www.soleno.life.